Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: The cardiovascular health study

American Journal of Kidney Diseases

Volumn 66, Issue 1, 2015, Pages 40-46

  Deo, Rajat ^a   Katz, Ronit ^b   De Boer, Ian H ^b,c   Sotoodehnia, Nona ^c   Kestenbaum, Bryan ^b,c   Mukamal, Kenneth J ^d   Chonchol, Michel ^e   Sarnak, Mark J ^f   Siscovick, David ^b,c,g   Shlipak, Michael G ^h,i,j   Ix, Joachim H ^k,l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g CENTER FOR HEALTH STUDIES   (United States)

^h SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

cardiovascular event; Cardiovascular Health Study (CHS); cardiovascular mortality; chronic kidney disease (CKD); cohort study; fatal arrhythmic event; Fibroblast growth factor 23 (FGF 23); non SCD; renal function; sudden cardiac death (SCD)

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART DEATH; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; TELEPHONE INTERVIEW; ADRENERGIC SYSTEM; BLOOD; COMPARATIVE STUDY; ELECTROCARDIOGRAPHY; HEART ARREST; HEART DISEASE; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COMORBIDITY; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HEART ARREST; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; UNITED STATES;

EID: 84937525511     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.10.025     Document Type: Article

References (30)

1. S. Liu, and L.D. Quarles How fibroblast growth factor 23 works J Am Soc Nephrol 18 6 2007 1637 1647
2. O. Gutierrez, T. Isakova, E. Rhee, and et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease J Am Soc Nephrol 16 7 2005 2205 2215
3. J.H. Ix, R. Katz, B.R. Kestenbaum, and et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study) J Am Coll Cardiol 60 3 2012 200 207
4. B.D. Parker, L.J. Schurgers, V.M. Brandenburg, and et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study Ann Intern Med 152 10 2010 640 648
5. T. Isakova, H. Xie, W. Yang, and et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease JAMA 305 23 2011 2432 2439
6. O.M. Gutierrez, M. Mannstadt, T. Isakova, and et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 359 6 2008 584 592
7. J.J. Scialla, H. Xie, M. Rahman, and et al. Fibroblast growth factor-23 and cardiovascular events in CKD J Am Soc Nephrol 25 2 2013 349 360
8. R. Deo, N. Sotoodehnia, R. Katz, and et al. Cystatin C and sudden cardiac death risk in the elderly Circ Cardiovasc Qual Outcomes 3 2 2010 159 164
9. I.R. Whitman, H.I. Feldman, and R. Deo CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches J Am Soc Nephrol 23 12 2012 1929 1939
10. C. Faul, A.P. Amaral, B. Oskouei, and et al. FGF23 induces left ventricular hypertrophy J Clin Invest 121 11 2011 4393 4408
11. O.M. Gutierrez, J.L. Januzzi, T. Isakova, and et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease Circulation 119 19 2009 2545 2552
12. R. Deo, and C.M. Albert Epidemiology and genetics of sudden cardiac death Circulation 125 4 2012 620 637
13. L.P. Fried, N.O. Borhani, P. Enright, and et al. The Cardiovascular Health Study: design and rationale Ann Epidemiol 1 3 1991 263 276
14. M.G. Shlipak, M.J. Sarnak, R. Katz, and et al. Cystatin C and the risk of death and cardiovascular events among elderly persons N Engl J Med 352 20 2005 2049 2060
15. P.E. Stevens, and A. Levin Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline Ann Intern Med 158 11 2013 825 830
16. K.B. Jonsson, R. Zahradnik, T. Larsson, and et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia N Engl J Med 348 17 2003 1656 1663
17. G.I. Fishman, S.S. Chugh, J.P. Dimarco, and et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop Circulation 122 22 2010 2335 2348
18. 2-adrenergic receptor genetic variants and risk of sudden cardiac death Circulation 113 15 2006 1842 1848
19. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 446 1999 496 509
20. Rebholz CM, Grams ME, Coresh J, et al. Serum fibroblast growth factor-23 is associated with incident kidney disease [published online ahead of print July 24, 2014]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2014020218.
21. M. Kawai, S. Kinoshita, S. Shimba, K. Ozono, and T. Michigami Sympathetic activation induces skeletal FGF23 expression in a circadian rhythm-dependent manner J Biol Chem 289 3 2014 1457 1466
22. E. de Beus, R. de Jager, J.A. Joles, G. Grassi, and P.J. Blankestijn Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J Hypertens 32 9 2014 1751 1761
23. V.G. Florea, and J.N. Cohn The autonomic nervous system and heart failure Circ Res 114 11 2014 1815 1826
24. A. Babick, V. Elimban, S. Zieroth, and N.S. Dhalla Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction J Cell Physiol 228 10 2013 2063 2070
25. W.S. Colucci The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure Clin Cardiol 21 12 suppl 1 1998 I20 I24
26. M.C. Hu, M. Shi, J. Zhang, and et al. Klotho deficiency causes vascular calcification in chronic kidney disease J Am Soc Nephrol 22 1 2011 124 136
27. H. Galitzer, I.Z. Ben-Dov, J. Silver, and T. Naveh-Many Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease Kidney Int 77 3 2010 211 218
28. S. Liu, W. Tang, J. Zhou, and et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D J Am Soc Nephrol 17 5 2006 1305 1315
29. R. Thadhani, E. Appelbaum, Y. Pritchett, and et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial JAMA 307 7 2012 674 684
30. L.E. Hinkle Jr., and H.T. Thaler Clinical classification of cardiac deaths Circulation 65 3 1982 457 464